Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer

The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encourag...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 30; no. 14; p. 1594
Main Authors:	Cortés, Javier, Fumoleau, Pierre, Bianchi, Giulia Valeria, Petrella, Teresa M, Gelmon, Karen, Pivot, Xavier, Verma, Shailendra, Albanell, Joan, Conte, Pierfranco, Lluch, Ana, Salvagni, Stefania, Servent, Veronique, Gianni, Luca, Scaltriti, Maurizio, Ross, Graham A, Dixon, Joanna, Szado, Tania, Baselga, José
Format:	Journal Article
Language:	English
Published:	United States 10.05.2012
Subjects:	Adult Age Factors Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Disease Progression Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Maximum Tolerated Dose Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Patient Selection Prognosis Prospective Studies Receptor, ErbB-2 - metabolism Risk Assessment Survival Analysis Trastuzumab Treatment Outcome
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!